» Articles » PMID: 25911238

Sample Conditions Determine the Ability of Thrombin Generation Parameters to Identify Bleeding Phenotype in FXI Deficiency

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2015 Apr 26
PMID 25911238
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Individuals with Factor XI (FXI) deficiency have a variable bleeding tendency that does not correlate with FXI:C levels or genotype. Comparing a range of sample conditions, we tested whether the thrombin generation assay (TGA) could discriminate between control subjects (n = 50) and FXI-deficient individuals (n = 97), and between those with bleeding tendency (n = 50) and without (n = 24). The comparison used platelet-rich plasma (PRP) and platelet-poor plasma (PPP), either with or without corn trypsin inhibitor (CTI) to prevent contact activation, over a range of tissue factor (TF) concentrations. When contact activation was inhibited and platelets were absent, FXI:C levels did not correlate with thrombin generation parameters, and control and FXI-deficient individuals were not distinguished. In all other sample types, the best discrimination was obtained using TF 0.5 pM and assay measures: endogenous thrombin potential (ETP) and peak height. We showed that although a number of conditions could distinguish differences between the groups tested, TGA measured in PRP with CTI best differentiated between bleeders and nonbleeders. These measures provided high sensitivity and specificity (peak height receiver operating characteristic [ROC] area under the curve [AUC] = 0.9362; P < .0001) (ETP ROC AUC = 0.9362; P < .0001). We conclude that by using sample conditions directed to test specific pathways of FXI activation, the TGA can identify bleeding phenotype in FXI deficiency.

Citing Articles

Abelacimab in Cancer-Associated Thrombosis: The Right Drug at the Right Time for the Right Purpose. A Comprehensive Review.

Fioretti A, Leopizzi T, La Forgia D, De Luca R, Oreste D, Inchingolo R Rev Cardiovasc Med. 2024; 24(10):295.

PMID: 39077577 PMC: 11262452. DOI: 10.31083/j.rcm2410295.


The foundation for investigating factor XI as a target for inhibition in human cardiovascular disease.

Ali A, Becker R J Thromb Thrombolysis. 2024; 57(8):1283-1296.

PMID: 38662114 PMC: 11645312. DOI: 10.1007/s11239-024-02985-0.


Concomitant hypofibrinogenemia and factor XI deficiency as rare cause of bleeding during urgent dentistry: case report and short review of the literature.

Sucker C, Geisen C, Litmathe J, Schmitt U Arch Clin Cases. 2023; 10(2):110-113.

PMID: 37405328 PMC: 10315684. DOI: 10.22551/2023.39.1002.10253.


High plasma levels of C1-inhibitor are associated with lower risk of future venous thromboembolism.

Grover S, Snir O, Hindberg K, Englebert T, Braekkan S, Morelli V J Thromb Haemost. 2023; 21(7):1849-1860.

PMID: 37003465 PMC: 11112258. DOI: 10.1016/j.jtha.2023.03.024.


Tissue factor pathway inhibitor is a potential modifier of bleeding risk in factor XI deficiency.

Reitsma S, Holle L, Bouck E, Monroe D, Mast A, Burthem J J Thromb Haemost. 2023; 21(3):467-479.

PMID: 36696199 PMC: 10111213. DOI: 10.1016/j.jtha.2022.10.005.